Simplex Trading’s Oncternal Therapeutics ONCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-3,250
Closed -$72K – 11187
2022
Q2
$72K Sell
3,250
-240
-7% -$5.35K ﹤0.01% 6006
2022
Q1
$97K Buy
3,490
+3,050
+693% +$111K ﹤0.01% 6200
2021
Q4
$19K Sell
440
-2,860
-87% -$192K ﹤0.01% 8440
2021
Q3
$314K Hold
3,300
– – ﹤0.01% 4837
2021
Q2
$313K Buy
3,300
+3,288
+27,400% +$390K ﹤0.01% 4911
2021
Q1
$194K Buy
12
+9
+300% +$1.19K ﹤0.01% 4795
2020
Q4
$28K Buy
+3
New +$190 ﹤0.01% 6731
2019
Q1
– Hold
0
– -$2K – 8065
2018
Q4
– Sell
-1
Closed -$200 – 6641
2018
Q3
$17K Buy
+1
New +$2.4K ﹤0.01% 6097
2016
Q1
– Hold
0
– -$13K – 6425
2015
Q4
– Hold
0
– – – 3101
2015
Q3
– Hold
0
– – – 3292
2015
Q2
– Hold
0
– – – 3085
2015
Q1
– Hold
0
– – – 2721
2014
Q4
– Hold
0
– – – 2481

Other funds holding ONCT

Simplex Trading's ONCT Position: Q2 2023 in Review

Simplex Trading sold out of Oncternal Therapeutics (ONCT) in Q2 2023, closing a stake of 356 shares — an estimated $5K sold.

Simplex Trading first reported a position in ONCT in Q4 2014 and held it in 17 quarters. The position peaked at $319K in Q1 2021. 52 funds tracked by Wall St. Rank hold ONCT as of Q2 2023.

  • Simplex Trading reported no remaining Oncternal Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Simplex Trading sold 356 Oncternal Therapeutics shares in Q2 2023, an estimated $5K.
  • Simplex Trading first reported a position in Oncternal Therapeutics in Q4 2014 and held it in 17 quarters.
  • Simplex Trading's Oncternal Therapeutics position peaked at $319K in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Oncternal Therapeutics as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.